How mRNA Vaccines Work: Mechanism, History and the 2026 Policy Split
Bottom line
An mRNA vaccine gives your muscle cells a short set of written instructions so they build one harmless piece of a germ, and your immune system learns to recognise it. CDC explains that the cells then break the mRNA down and the body clears it, and that these vaccines do not enter the cell nucleus where DNA is kept. The most important thing to know now is that the science is settled enough to have won a Nobel Prize, but the politics are not: in the United States the FDA approved the first mRNA flu vaccine on 5 August 2026, while the federal health department had ended its mRNA vaccine development funding a year earlier.
Interpretation note: "mRNA vaccines" here means the vaccine class (COVID-19 shots from Pfizer-BioNTech and Moderna, and newer products), not any one product. This report explains how things work and what the evidence says. It is not medical advice.
How it works
Step 1, the instructions. Messenger RNA (mRNA) is a single-stranded molecule that carries genetic information from DNA to direct the making of proteins. In a vaccine, the mRNA is made in a laboratory and encodes a protein, or just a piece of one, from the target germ. For COVID-19 that is a piece of the spike protein on the virus surface.
Step 2, the delivery. Bare mRNA is fragile and hard to deliver, so the Nobel Committee notes that it needed sophisticated carrier lipid (fat) systems to encapsulate it. The shot is given into the upper arm or thigh muscle.
Step 3, the factory. Inside muscle cells, the mRNA uses the cells' own machinery to make the protein piece. After that, the cells break down the mRNA and it leaves the body as waste. CDC gives no exact time for this, and I did not find a source in this run that does.
Step 4, the lesson. The cells show the protein piece on their surface. The immune system sees that it does not belong, and makes antibodies and activates other immune cells. Afterwards the body keeps memory T-lymphocytes and B-lymphocytes that remember how to fight that germ, a process that typically takes a few weeks. Fever after vaccination can be one of the normal signs the body is building immunity.
Why the Nobel went to base modification. Plain lab-made mRNA triggered inflammation. Karikó and Weissman found that swapping in chemically modified bases almost abolished the inflammatory response and increased protein production. Both approved COVID-19 vaccines use base-modified mRNA.
Why it can be fast. Older vaccines need large-scale cell culture, which limits rapid production. mRNA does not. My inference: to change the target, makers change the written sequence, which is why the same platform can be pointed at flu, cancer and other diseases.
An analogy, accurate only in outline: the vaccine is a short-lived recipe card handed to a kitchen, not a new kitchen. The kitchen (the cell) cooks one dish, the immune system tastes it, and the card is thrown away.
Key history and dates
| Date | Event | Why it matters | Source |
|---|---|---|---|
| 1980s | Methods to make mRNA without cell culture (in vitro transcription) introduced | Made mRNA a practical lab tool | Nobel press release |
| Early 1990s | Karikó pursues mRNA therapy at University of Pennsylvania despite funding difficulty | Shows how long the idea waited | Nobel press release |
| 2005 | Karikó and Weissman publish base-modification finding | Removed the main inflammation obstacle | Nobel press release |
| 2008 and 2010 | Follow-up papers show more protein production | Made mRNA potent enough for vaccines | Nobel press release |
| Dec 2020 | Two base-modified COVID-19 mRNA vaccines approved, with protection of around 95% reported | First mass use of the platform | Nobel press release |
| 2 Oct 2023 | Nobel Prize in Physiology or Medicine to Karikó and Weissman | Recognised the discovery; the committee counts over 13 billion COVID-19 vaccine doses of all types given globally | Nobel press release |
| 25 Jun 2025 | FDA requires updated myocarditis warning on Pfizer and Moderna labels | Quantified a known rare risk | FDA safety communication |
| 5 Aug 2025 | HHS announces wind-down of BARDA mRNA vaccine work, 22 projects, nearly $500 million | Major US funding reversal | HHS press release |
| 5 Aug 2026 | FDA approves Moderna's mFLUSIVA, first mRNA flu vaccine, for adults 50 and older | First mRNA vaccine beyond COVID-19 in the US | CNN |
Current state
Dates below are event dates as reported by the cited article.
- Flu vaccine approved (5 Aug 2026). Moderna's study of over 40,000 adults aged 50 and older found the shot about 27% more effective than standard flu shots in the 2024 to 2025 season. Approval was traditional for ages 50 to 64 and accelerated for 65 and older, which requires further trials. Both are Moderna's study figures as relayed by CNN.
- Rocky path. In February 2026 the FDA declined to review the application, then reversed about two weeks later. In June an FDA advisory panel voted unanimously that benefits outweigh risks.
- Europe. A combined flu and COVID-19 mRNA vaccine from Moderna was approved in Europe earlier in 2026 (CNN's account; I did not open the underlying Reuters report).
- Vaccine advisers in limbo. A federal judge ruled in March 2026 that Kennedy did not follow legal procedure when replacing all members of CDC's vaccine advisory committee. It had not met since, with a meeting scheduled for October.
- Cancer vaccines. In a pancreatic cancer trial, 8 of 16 patients had a dramatic immune response and 7 of those 8 were alive six years on. Study size is small and a larger trial is running. Moderna and Merck announced in January 2026 that their personalised melanoma therapy cut the death rate by 49% over five years, a company announcement; a phase 3 trial continues.
- Safety numbers. For the 2023 to 2024 formula, about 8 myocarditis or pericarditis cases per million doses in people 6 months to 64 years, and about 27 per million in males 12 to 24, measured in the 1 to 7 days after vaccination (unadjusted claims-data estimates).
KEY TAKEAWAY: The platform is expanding into flu and cancer in 2026 even as US federal support for infectious-disease mRNA has narrowed.
Main debates
| Debate | Side A's best case | Side B's best case | What would settle it |
|---|---|---|---|
| Should governments fund mRNA vaccines? | HHS Secretary Kennedy said the data show these vaccines "fail to protect effectively against upper respiratory infections like COVID and flu" and funding should go to other platforms. FDA's Makary said mRNA makers earned over $50 billion and can fund their own research. | CNN describes the efficacy claim as made "against evidence"; CNN reports that political backlash threatened to slow or derail dozens of potential cancer treatments, though grants have started to flow again. | Head-to-head trials against other platforms, and the results of Moderna's accelerated-approval follow-up |
| How serious is the heart-inflammation risk? | FDA says the risk is highest in males 12 to 24 and abnormal heart MRI findings were common at about 5 months. | The same notice says the significance of those MRI findings is not known; cancer researcher Jaffee says with two billion-plus injections there is no data showing serious problems (her view, not a formal review). | The long-term heart studies the FDA has required from both makers, which are underway |
| Is the new flu shot a real improvement? | Moderna's study found about 27% more effectiveness than standard flu shots, and the shorter strain-selection gap could allow a closer match to circulating flu. | The FDA first cited inadequate trials, and for ages 65 and up clinical benefit still has to be proven. | Confirmatory trials and real-world seasons |
Common misconceptions
| Misconception | What is actually true | Source |
|---|---|---|
| mRNA vaccines change your DNA | They do not enter the nucleus where DNA is kept, so they cannot change genes | CDC |
| The vaccine can give you COVID-19 | No live virus is used, so it cannot cause infection | CDC |
| The mRNA lingers in the body | Cells break it down and remove it | CDC |
| The technology appeared overnight in 2020 | Key discoveries date to 2005 and mRNA vaccines for other germs were studied earlier, including flu, Zika, rabies and CMV | Nobel, CDC |
| Trial phases were skipped | CDC states no trial phases were skipped | CDC |
| There are no side effects or risks | Common effects are sore arm, headache, chills, fever. Myocarditis is rare but real, with a required label warning | CDC, FDA |
| mRNA is only for COVID-19 | A flu vaccine is now approved and cancer vaccines are in trials | CNN |
Reading list
Only pages I opened in this run are listed, so it skews toward official and news sources.
| Title | Author/Publisher | Level | Why read it | Link |
|---|---|---|---|---|
| COVID-19 Vaccine Basics | CDC, 3 Sep 2024 | Beginner | Plain step-by-step mechanism and safety monitoring | CDC |
| Nobel Prize 2023 press release | Nobel Assembly, 2 Oct 2023 | Intermediate | Best short account of why mRNA vaccines became possible | Nobel |
| FDA myocarditis safety communication | FDA, 25 Jun 2025 | Intermediate | Primary source for the safety numbers | FDA |
| HHS winds down mRNA work under BARDA | HHS, 5 Aug 2025 | Intermediate | The government's own case for the funding cut | HHS |
| After a year of turmoil, cancer researchers see promising signs | CNN, 20 Apr 2026 | Intermediate | Cancer vaccines and the funding fight | CNN |
| FDA approves first mRNA-based flu vaccine | CNN, 5 Aug 2026 | Intermediate | Latest milestone | CNN |
Open questions and limits of this report
- Not accessed: I did not open the peer-reviewed papers, the FDA approval letter for mFLUSIVA, or the Nobel "scientific background" PDF. The 27% and 49% figures come from company statements as relayed by CNN.
- Unknown: how long the mRNA and spike protein persist after injection (CDC says only that cells break it down). Whether heart MRI changes after myocarditis matter long term is not known.
- Contested: Kennedy's efficacy claim versus CNN's characterisation of it as against evidence; I did not independently review the data he cited.
- Not covered in depth: non-US regulators, global access, and lipid nanoparticle chemistry beyond the Nobel summary. Several 2026 events rest on a single news report.
Sources
- CDC, COVID-19 Vaccine Basics (3 September 2024)
- Nobel Assembly, Press release, 2023 Nobel Prize in Physiology or Medicine (2 October 2023)
- FDA, Updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines (25 June 2025)
- HHS, HHS Winds Down mRNA Vaccine Development Under BARDA (5 August 2025)
- CNN, After a year of turmoil, cancer researchers see promising signs for mRNA vaccines (20 April 2026)
- CNN, FDA approves first mRNA-based flu vaccine (5 August 2026)